Alliance A031501: AMBASSADOR study of Adjuvant Pembrolizumab (Pembro) in Muscle-Invasive Urothelial Carcinoma (MIUC) vs Observation (Obs): Extended follow-up results and metastatic disease recurrence distribution
- Citation:
- Meeting Instance:
- ESMO 2024
- Year:
- 2024
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 4435
- Pharmas:
- Merck Sharp & Dohme Corp
- Grants:
- U10CA180821, U10CA180882; U10CA180820 (ECOG-ACRIN); U10CA180888 (SWOG);
- Corr. Author:
- Authors:
- Andrea B. Apolo Karla V. Ballman Guru Sonpavde Stephanie Berg William Y. Kim Rahul Parikh Min Yuen Teo Randy F. Sweis Daniel Geynisman Petros Grivas Gurkamal Chatta Zachery Roger Reichert Joseph Woong Kim Mehmet Asim Bilen Bradley McGregor Sandy Srinivas Susan Halabi Gabriela Perez Burbano Michael J. Morris Jonathan E. Rosenberg
- Networks:
- FL086, KANSAS, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-NY158, MD001
- Study
- Alliance-A031501
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: